Anastrozole

Anastrozole

Clinical data
Routes of administration	oral
ATC code	L02BG03 (WHO)
Legal status
Legal status	Rx only (U.S.)
Pharmacokinetic data
Bioavailability	83-85%
Protein binding	40%
Metabolism	85% hepatic
Elimination half-life	72 hours
Excretion	11% renal
Identifiers
IUPAC name 2-[3-(1-cyano-1-methyl-ethyl)- 5-(1H-1,2,4-triazol-1-ylmethyl)phenyl]- 2-methyl- propanenitrile
CAS Number	120511-73-1
PubChem CID	2187
DrugBank	APRD00016
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}
Chemical and physical data
Formula	C17H19N5
Molar mass	293.366 g/mol

WikiDoc Resources for Anastrozole
Articles
Most recent articles on Anastrozole Most cited articles on Anastrozole Review articles on Anastrozole Articles on Anastrozole in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Anastrozole Images of Anastrozole Photos of Anastrozole Podcasts & MP3s on Anastrozole Videos on Anastrozole
Evidence Based Medicine
Cochrane Collaboration on Anastrozole Bandolier on Anastrozole TRIP on Anastrozole
Clinical Trials
Ongoing Trials on Anastrozole at Clinical Trials.gov Trial results on Anastrozole Clinical Trials on Anastrozole at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Anastrozole NICE Guidance on Anastrozole NHS PRODIGY Guidance FDA on Anastrozole CDC on Anastrozole
Books
Books on Anastrozole
News
Anastrozole in the news Be alerted to news on Anastrozole News trends on Anastrozole
Commentary
Blogs on Anastrozole
Definitions
Definitions of Anastrozole
Patient Resources / Community
Patient resources on Anastrozole Discussion groups on Anastrozole Patient Handouts on Anastrozole Directions to Hospitals Treating Anastrozole Risk calculators and risk factors for Anastrozole
Healthcare Provider Resources
Symptoms of Anastrozole Causes & Risk Factors for Anastrozole Diagnostic studies for Anastrozole Treatment of Anastrozole
Continuing Medical Education (CME)
CME Programs on Anastrozole
International
Anastrozole en Espanol Anastrozole en Francais
Business
Anastrozole in the Marketplace Patents on Anastrozole
Experimental / Informatics
List of terms related to Anastrozole

Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [1] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.

Overview

Anastrozole (INN, trade name: Arimidex®) is a drug indicated in the treatment of breast cancer in post-menopausal women. It is used both in adjuvant therapy (i.e. following surgery) and in metastatic breast cancer. It has the effect of decreasing the amount of estrogens that the body makes.

Anastrozole belongs in the class of drugs known as aromatase inhibitors. It inhibits the enzyme aromatase, which is responsible for converting androgens (produced by women in the adrenal glands) to estrogens.

The ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial represents a long-term follow-up study of 9366 women with localized breast cancer who received either anastrozole, tamoxifen, or both. After more than 5 years the group that received anastrozole had significantly better clinical results than the tamoxifen group. The trial suggested that anastrozole is the preferred medical therapy for postmenopausal women with localized breast cancer that is estrogen receptor positive.

Usage for men

While officially indicated for women, this drug has proven effective in the off-label use of reducing estrogens (in particular and more importantly, estradiol) in men. Excess estradiol in men can cause benign prostatic hyperplasia, gynecomastia, and symptoms of hypogonadism. Some athletes and body builders will also use anastrozole as a part of their steroid cycle to reduce and prevent symptoms of excess estrogens; in particular, gynecomastia and water retention.

Study data currently suggests that dosages of 0.5mg to 1mg a day reduce serum estradiol by about 50% in men, which differs from the typical reduction in postmenopausal women. However the reduction may be different for men with grossly elevated estradiol (clinical data is currently lacking).

Usage for children

This drug is frequently used in the treatment of growth disorder affected children to stop or slow the onset of puberty. The treatment of the growth disorder is through hormones which may trigger the early onset of puberty (precocious puberty). At the onset of puberty the bone growth plates begin to close. This can occur in children as young as 5 years old so for children severely behind in growth, the opportunity for increased growth is diminished. Arimidex is shown to slow or stop this process.

External links

• Arimidex.com - Information about Arimidex and breast cancer